Close

Spectrum Pharma (SPPI) Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing

Go back to Spectrum Pharma (SPPI) Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing

Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing

September 23, 2022 7:00 AM EDT

-- Multiple tranche debt financing provides Spectrum with up to $65 million --

-- Funding provides additional capital to optimize commercial launch of ROLVEDON --

-- Cash runway extended through 2024 --

BOSTON--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (Spectrum or the Company), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it has entered into a five-year debt financing agreement with investment affiliates managed by SLR Capital Partners, LLC (SLR) for a term loan facility of up to $65 million.... More